Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells

Daniel P. Sherbet, Oleg L. Guryev, Mahboubeh Papari-Zareei, Dario Mizrachi, Siayareh Rambally, Sharareh Akbar, Richard J. Auchus

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Human 17β-hydroxysteroid dehydrogenase types 1 and 2 (17βHSD1 and 17βHSD2) regulate estrogen potency by catalyzing the interconversion of estrone (E1) and estradiol (E2) using nicotinamide adenine dinucleotide (phosphate) cofactors NAD(P)(H). In intact cells, 17βHSD1 and 17βHSD2 establish pseudo-equilibria favoring E1 reduction or E2 oxidation, respectively. The vulnerability of these equilibrium steroid distributions to mutations and to altered intracellular cofactor abundance and redox state, however, is not known. We demonstrate that the equilibrium E2/E1 ratio achieved by 17βHSD1 in intact HEK-293 cell lines is progressively reduced from 94:6 to 10:90 after mutagenesis of R38, which interacts with the 2′-phosphate of NADP(H), and by glucose deprivation, which lowers the NADPH/NADP+ ratio. The shift to E2 oxidation parallels changes in apparent Km values for purified 17βHSD1 proteins to favor NAD(H) over NADP(H). In contrast, mutagenesis of E116 (corresponding to R38 in 17βHSD1) and changes in intracellular cofactor ratios do not alter the greater than 90:10 E1/E2 ratio catalyzed by 17βHSD2, and these mutations lower the apparent Km of recombinant 17βHSD2 for NADP(H) only less than 3-fold. We conclude that the equilibrium E1/E2 ratio maintained by human 17βHSD1 in intact cells is governed by NADPH saturation, which is strongly dependent on both R38 and high intracellular NADPH/NADP+ ratios. In contrast, the preference of 17βHSD2 for E2 oxidation strongly resists alteration by genetic and metabolic manipulations. These findings suggest that additional structural features, beyond the lack of a specific arginine residue, disfavor NADPH binding and thus support E2 oxidation by 17βHSD2 in intact cells.

Original languageEnglish (US)
Pages (from-to)4154-4162
Number of pages9
JournalEndocrinology
Volume150
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Estrone
HEK293 Cells
NADP
Estradiol
Mutagenesis
NAD
human HSD17B2 protein
Mutation
Oxidation-Reduction
Arginine
3 (or 17)-beta-hydroxysteroid dehydrogenase
Estrogens
Steroids
Phosphates
Glucose

ASJC Scopus subject areas

  • Endocrinology

Cite this

Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells. / Sherbet, Daniel P.; Guryev, Oleg L.; Papari-Zareei, Mahboubeh; Mizrachi, Dario; Rambally, Siayareh; Akbar, Sharareh; Auchus, Richard J.

In: Endocrinology, Vol. 150, No. 9, 09.2009, p. 4154-4162.

Research output: Contribution to journalArticle

Sherbet, Daniel P. ; Guryev, Oleg L. ; Papari-Zareei, Mahboubeh ; Mizrachi, Dario ; Rambally, Siayareh ; Akbar, Sharareh ; Auchus, Richard J. / Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells. In: Endocrinology. 2009 ; Vol. 150, No. 9. pp. 4154-4162.
@article{86c4456f425a43c68b8beba30d1a530e,
title = "Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells",
abstract = "Human 17β-hydroxysteroid dehydrogenase types 1 and 2 (17βHSD1 and 17βHSD2) regulate estrogen potency by catalyzing the interconversion of estrone (E1) and estradiol (E2) using nicotinamide adenine dinucleotide (phosphate) cofactors NAD(P)(H). In intact cells, 17βHSD1 and 17βHSD2 establish pseudo-equilibria favoring E1 reduction or E2 oxidation, respectively. The vulnerability of these equilibrium steroid distributions to mutations and to altered intracellular cofactor abundance and redox state, however, is not known. We demonstrate that the equilibrium E2/E1 ratio achieved by 17βHSD1 in intact HEK-293 cell lines is progressively reduced from 94:6 to 10:90 after mutagenesis of R38, which interacts with the 2′-phosphate of NADP(H), and by glucose deprivation, which lowers the NADPH/NADP+ ratio. The shift to E2 oxidation parallels changes in apparent Km values for purified 17βHSD1 proteins to favor NAD(H) over NADP(H). In contrast, mutagenesis of E116 (corresponding to R38 in 17βHSD1) and changes in intracellular cofactor ratios do not alter the greater than 90:10 E1/E2 ratio catalyzed by 17βHSD2, and these mutations lower the apparent Km of recombinant 17βHSD2 for NADP(H) only less than 3-fold. We conclude that the equilibrium E1/E2 ratio maintained by human 17βHSD1 in intact cells is governed by NADPH saturation, which is strongly dependent on both R38 and high intracellular NADPH/NADP+ ratios. In contrast, the preference of 17βHSD2 for E2 oxidation strongly resists alteration by genetic and metabolic manipulations. These findings suggest that additional structural features, beyond the lack of a specific arginine residue, disfavor NADPH binding and thus support E2 oxidation by 17βHSD2 in intact cells.",
author = "Sherbet, {Daniel P.} and Guryev, {Oleg L.} and Mahboubeh Papari-Zareei and Dario Mizrachi and Siayareh Rambally and Sharareh Akbar and Auchus, {Richard J.}",
year = "2009",
month = "9",
doi = "10.1210/en.2008-1817",
language = "English (US)",
volume = "150",
pages = "4154--4162",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17β-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells

AU - Sherbet, Daniel P.

AU - Guryev, Oleg L.

AU - Papari-Zareei, Mahboubeh

AU - Mizrachi, Dario

AU - Rambally, Siayareh

AU - Akbar, Sharareh

AU - Auchus, Richard J.

PY - 2009/9

Y1 - 2009/9

N2 - Human 17β-hydroxysteroid dehydrogenase types 1 and 2 (17βHSD1 and 17βHSD2) regulate estrogen potency by catalyzing the interconversion of estrone (E1) and estradiol (E2) using nicotinamide adenine dinucleotide (phosphate) cofactors NAD(P)(H). In intact cells, 17βHSD1 and 17βHSD2 establish pseudo-equilibria favoring E1 reduction or E2 oxidation, respectively. The vulnerability of these equilibrium steroid distributions to mutations and to altered intracellular cofactor abundance and redox state, however, is not known. We demonstrate that the equilibrium E2/E1 ratio achieved by 17βHSD1 in intact HEK-293 cell lines is progressively reduced from 94:6 to 10:90 after mutagenesis of R38, which interacts with the 2′-phosphate of NADP(H), and by glucose deprivation, which lowers the NADPH/NADP+ ratio. The shift to E2 oxidation parallels changes in apparent Km values for purified 17βHSD1 proteins to favor NAD(H) over NADP(H). In contrast, mutagenesis of E116 (corresponding to R38 in 17βHSD1) and changes in intracellular cofactor ratios do not alter the greater than 90:10 E1/E2 ratio catalyzed by 17βHSD2, and these mutations lower the apparent Km of recombinant 17βHSD2 for NADP(H) only less than 3-fold. We conclude that the equilibrium E1/E2 ratio maintained by human 17βHSD1 in intact cells is governed by NADPH saturation, which is strongly dependent on both R38 and high intracellular NADPH/NADP+ ratios. In contrast, the preference of 17βHSD2 for E2 oxidation strongly resists alteration by genetic and metabolic manipulations. These findings suggest that additional structural features, beyond the lack of a specific arginine residue, disfavor NADPH binding and thus support E2 oxidation by 17βHSD2 in intact cells.

AB - Human 17β-hydroxysteroid dehydrogenase types 1 and 2 (17βHSD1 and 17βHSD2) regulate estrogen potency by catalyzing the interconversion of estrone (E1) and estradiol (E2) using nicotinamide adenine dinucleotide (phosphate) cofactors NAD(P)(H). In intact cells, 17βHSD1 and 17βHSD2 establish pseudo-equilibria favoring E1 reduction or E2 oxidation, respectively. The vulnerability of these equilibrium steroid distributions to mutations and to altered intracellular cofactor abundance and redox state, however, is not known. We demonstrate that the equilibrium E2/E1 ratio achieved by 17βHSD1 in intact HEK-293 cell lines is progressively reduced from 94:6 to 10:90 after mutagenesis of R38, which interacts with the 2′-phosphate of NADP(H), and by glucose deprivation, which lowers the NADPH/NADP+ ratio. The shift to E2 oxidation parallels changes in apparent Km values for purified 17βHSD1 proteins to favor NAD(H) over NADP(H). In contrast, mutagenesis of E116 (corresponding to R38 in 17βHSD1) and changes in intracellular cofactor ratios do not alter the greater than 90:10 E1/E2 ratio catalyzed by 17βHSD2, and these mutations lower the apparent Km of recombinant 17βHSD2 for NADP(H) only less than 3-fold. We conclude that the equilibrium E1/E2 ratio maintained by human 17βHSD1 in intact cells is governed by NADPH saturation, which is strongly dependent on both R38 and high intracellular NADPH/NADP+ ratios. In contrast, the preference of 17βHSD2 for E2 oxidation strongly resists alteration by genetic and metabolic manipulations. These findings suggest that additional structural features, beyond the lack of a specific arginine residue, disfavor NADPH binding and thus support E2 oxidation by 17βHSD2 in intact cells.

UR - http://www.scopus.com/inward/record.url?scp=69249127192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249127192&partnerID=8YFLogxK

U2 - 10.1210/en.2008-1817

DO - 10.1210/en.2008-1817

M3 - Article

C2 - 19556422

AN - SCOPUS:69249127192

VL - 150

SP - 4154

EP - 4162

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -